Home > Haematology > EHA 2020 > Graft-Versus-Host Disease > GRAVITAS-301: improved complete aGVDH response

GRAVITAS-301: improved complete aGVDH response

Presented By
Prof. Robert Zeiser, University Hospital Freiburg, Germany
Conference
EHA 2020
Trial
Phase 3, GRAVITAS-301
Although GRAVITAS-301 missed its primary endpoint, post-hoc analysis showed a significant effect of itacitinib in complete response at day 28 in patients with treatment-naive acute graft-versus-host disease (aGVHD). Prof. Robert Zeiser (University Hospital Freiburg, Germany) presented the results and a post-hoc analysis from the phase 3 randomised, double-blind GRAVITAS-301 trail [1]. GRAVITAS-301 evaluated itacitinib, a JAK-1 inhibitor in combination with corticosteroids in patients with treatment-naïve aGVHD. The primary endpoint was improvement of overall response rate (ORR) at day 28. The key secondary endpoint was 6-month non-relapse mortality (NRM). Included were adult patients (n=439) receiving allogeneic haematopoietic stem cell transplant (HSCT) for a haematologic malignancy who developed grade II–IV GVHD per MAGIC criteria. Patients were stratified...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on